Molecular diagnostics of acute myeloid leukemia it's a (next) generational thing

Journal of Molecular Diagnostics

Volumn 15, Issue 1, 2013, Pages 27-30

  Wertheim, Gerald B W ^a   Daber, Robert ^b   Bagg, Adam ^c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASXL1 PROTEIN; CEBPA PROTEIN; DNA; DNA METHYLTRANSFERASE 3A; FLT3 LIGAND; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; K RAS PROTEIN; NUCLEOPHOSMIN; PROTEIN; TET2 PROTEIN; UNCLASSIFIED DRUG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALGORITHM; ALLELE; CANCER DIAGNOSIS; CANCER PROGNOSIS; DNA SEQUENCE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KARYOTYPING; MOLECULAR DIAGNOSIS; NOTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84875437312     PISSN: 15251578     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2012.08.002     Document Type: Note

References (21)

1. American Cancer Society: Cancer Facts & Figures 2011. Atlanta, GA, American Cancer Society, 2011
2. Dixon-McIver A, East P, Mein CA, Cazier JB, Molloy G, Chaplin T, Andrew Lister T, Young BD, Debernardi S: Distinctive patterns of microRNA expression associated with karyotype in acute myeloid leukaemia. PLoS One 2008, 3:e2141
3. Figueroa ME, Lugthart S, Li Y, Erpelinck-Verschueren C, Deng X, Christos PJ, Schifano E, Booth J, van Putten W, Skrabanek L, Campagne F, Mazumdar M, Greally JM, Valk PJ, Löwenberg B, Delwel R, Melnick A: DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17:13-27
4. Grimwade D, Mrózek K: Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. Hematol Oncol Clin North Am 2011, 25:1135-1161, vii
5. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, Van Vlierberghe P, Dolgalev I, Thomas S, Aminova O, Huberman K, Cheng J, Viale A, Socci ND, Heguy A, Cherry A, Vance G, Higgins RR, Ketterling RP, Gallagher RE, Litzow M, van den Brink MR, Lazarus HM, Rowe JM, Luger S, Ferrando A, Paietta E, Tallman MS, Melnick A, Abdel-Wahab O, Levine RL: Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366:1079-1089
6. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Löwenberg B, Delwel R: Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004, 350:1617-1628
7. Morrissette JJ, Bagg A: Acute myeloid leukemia: conventional cytogenetics, FISH, and moleculocentric methodologies. Clin Lab Med 2011, 31:659-686, x
8. Watt CD, Bagg A: Molecular diagnosis of acute myeloid leukemia. Expert Rev Mol Diagn 2010, 10:993-1012
9. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (Ed): WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. ed 4. Lyon, IARC Press, 2008. pp. 118-123
10. NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia Version 2.2012. Fort Washington, PA, National Comprehensive Cancer Network, 2012. pp MS1-MS9
11. Spencer DH, Abel HJ, Lockwood CM, Payton JE, Szankasi P, Kelley TW, Kulkarni S, Pfeifer JD, Duncavage EJ: Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data. J Mol Diagn 2013, 15:81-93
12. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR: Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995, 3: 147-161
13. Foran JM: New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematology Am Soc Hematol Educ Program 2010, 2010:47-55
14. Mead AJ, Gale RE, Hills RK, Gupta M, Young BD, Burnett AK, Linch DC: Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. Blood 2008, 112:444-445
15. Greenblatt S, Li L, Slape C, Nguyen B, Novak R, Duffield A, Huso D, Desiderio S, Borowitz MJ, Aplan P, Small D: Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model. Blood 2012, 119: 2883-2894
16. Smith CC, Wang Q, Chin CS, Salerno S, Damon LE, Levis MJ, Perl AE, Travers KJ, Wang S, Hunt JP, Zarrinkar PP, Schadt EE, Kasarskis A, Kuriyan J, Shah NP: Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia. Nature 2012, 485:260-263
17. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, Linch DC, Medical Research Council Adult Leukaemia Working Party: The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111: 2776-2784
18. Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC: Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 2002, 100:2393-2398
19. Bubán T, Koczok K, Földesi R, Szabó G, Sümegi A, Tanyi M, Szerafin L, Udvardy M, Kappelmayer J, Antal-Szalmás P: Detection of internal tandem duplications in the FLT3 gene by different electrophoretic methods. Clin Chem Lab Med 2011, 50:301-310
20. King RL, Naghashpour M, Watt CD, Morrissette JJ, Bagg A: A comparative analysis of molecular genetic and conventional cytogenetic detection of diagnostically important translocations in more than 400 cases of acute leukemia, highlighting the frequency of falsenegative conventional cytogenetics. Am J Clin Pathol 2011, 135: 921-928
21. Thol F, Kölking B, Damm F, Reinhardt K, Klusmann JH, Reinhardt D, von Neuhoff N, Brugman MH, Schlegelberger B, Suerbaum S, Krauter J, Ganser A, Heuser M: Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer 2012, 51:689-695